Teva Defends Vincristine Discontinuation Decision

Insists It Is Not Responsible For US Shortages

 
• By Aidan Fry

Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.

Vincristine_NYT
Mainstream media in the US have run emotive reports on vincristine shortages • Source: New York Times

More from Manufacturing

More from Business